ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RAPP
SNDX (17) VSTM (36) AMPH (72) SLN (44) ⌘ Pro Terminal →

Rapport Therapeutics Inc. (RAPP) — RQD Stock Rating Cockpit

$25.05 +3.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $25.16

Rapport Therapeutics Inc. (RAPP) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $1.20B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RAPP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $25.05 (+3.47% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RAPP ranks #788 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RAPP compare to SNDX and VSTM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and VSTM (Verastem Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RAPP?
▼

Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $0 in revenue, -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $25.16 (+0.43%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (4)SEC (10)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$56 Bull$22 Base$17 Bear
📬 FREE RAPP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RAPP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY RAPP SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$28.99+1.3% Next Q
Q2 (-2Q)
35
Grade E$29.37-6.2% Next Q
Q3 (-1Q)
33
Grade E$27.54-9% Next Q
Current
30
Grade E$25.05-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RAPP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RAPP currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($35.74) and Max Pain ($26.30) forces dealer call-delta covering toward $55.58.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RAPP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RAPP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
38.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE10% OF RANGE
L: $22$25.05H: $53
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 16 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on RAPP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-22.9% ROIC with 42.0% gross margin and -7.58% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

7/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like RAPP
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RAPP)

  • ✓Walkthrough of RAPP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RAPP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -29.50%📐 HORIZONTAL RANGE
2026-11-03O $24.21H $25.05L $24.21C $25.05VOL 926.6K
RES: $60.43SUP: $21.64SMA50: $35.74SMA200: $35.63
$55.09$46.14$37.19$28.23$19.28RES $60.43SUP $21.64$25.052026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RAPP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RAPP Butterfly Map → + Track RAPP →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RAPP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RAPP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RAPP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RAPP)

Health Care Rank #788 of 1016 ⚔️ SNDX vs RAPP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RAPP vs. SNDX, VSTM, AMPH, SLN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Rapport Therapeutics Inc. (RAPP) ranks #788 by composite RQD confidence (30/100, grade E) and #334 by equity capitalization ($1.20B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with RAPP at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RAPP ACTIVE
Rapport Therapeutics Inc.
E 30/100 — — -22.9% +3.47% $1.20B Benchmark Subject
SNDX
Syndax Pharmaceuticals Inc.
E 17/100 — — -35.0% -3.53% $1.22B /sndx-vs-rapp →
VSTM
Verastem Inc.
D- 36/100 — — -35.0% +0.93% $1.18B /vstm-vs-rapp →
AMPH
Amphastar Pharmaceuticals Inc.
B 72/100 11.7x 49.5% 9.0% +2.93% $1.18B /amph-vs-rapp →
SLN
Silence Therapeutics Plc American Depository Share
D 44/100 — 61.5% -35.0% -0.25% $1.23B /sln-vs-rapp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002012593

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rapport Therapeutics Inc. (RAPP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$111.5M, operating cash flow of -$87.5M, and free cash flow of -$88.1M (-31.0% YoY). On the balance sheet, RAPP closed FY2025 with $512.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $0 -$111.5M -$87.5M -$88.1M $512.4M —
FY2024 (FY) 2024-12-31 $0 -$78.3M -$64.8M -$67.2M $314.9M —
FY2023 (FY) 2023-12-31 $0 -$34.8M -$27.2M -$27.2M — —

3. RAPP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RAPP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rapport Therapeutics Inc. (NASDAQ: RAPP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $25.05 (+3.47% 1D, market cap $1.20B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RAPP ranks #788 in composite RQD confidence.

How does RAPP compare to SNDX and VSTM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RAPP carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -22.9%. By comparison, SNDX (Syndax Pharmaceuticals Inc.) holds a E grade (17/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B) and VSTM (Verastem Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RAPP?

Per RAPP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002012593), Rapport Therapeutics Inc. generated $0 in revenue, -$111.5M in net income, and -$88.1M in free cash flow against $512.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RAPP trading relative to its 50-day, 200-day, and 52-week technical levels?

RAPP last traded at $25.05 (+3.47% on volume of 926,646 shares), positioning the stock -29.91% below its 50-day simple moving average ($35.74) and -29.69% below its 200-day simple moving average ($35.63). Across its 52-week range of $22.06 to $52.93, RAPP sits at the 9.7% percentile with a 14-day RSI of 38.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($21.92 to $28.18).

RAPP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell RAPP stock right now?

Rapport Therapeutics Inc. (RAPP) currently earns a Roarable Rating of E (Strong Sell — SELL) with 30/100 RQD Confidence. Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.

What is RAPP's 12-month price target and RQD AI Jury consensus?

RAPP's 12-month base price target is $21.89 (range $17.07 to $55.58), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: RAPP RQD Cockpit RAPP 12M Forecast RAPP Earnings & Move RAPP Dividends & DRIP RAPP Insiders & 13F RAPP Whale Options RAPP Profit Sankey RAPP News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RAPP — Rapport Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:30:27Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, RAPP carries an RQD score of 31 out of 100, a letter grade of E, and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars score as follows:

  • Fundamental cash engine: 7 / 20. The rating cites ROIC of -22.9% and an FCF yield of -7.58%. For a prospective investor, this means the business is consuming cash rather than generating it, so any valuation rests on future outcomes not yet visible in reported results.
  • Whale / 13F flow: 5 / 20. The rating reflects institutional accumulation and options positioning, which is weak here. Institutional conviction is a supportive signal for many stocks; its absence removes one common source of upside confirmation.
  • Insider conviction: 3 / 20. The rating cites an SEC Form 4 and congressional PTR cluster flow. This is the lowest pillar and indicates limited insider-side support for the equity.
  • Macro regime fit: 6 / 20. The rating shows a beta of 1.0 and sector sensitivity. The stock moves in line with the broader market, offering no defensive cushion or macro tailwind identified in the source data.
  • Forensic balance sheet: 10 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski score is weak, which signals deteriorating fundamentals across multiple tests, while the Z-Score sits in a range that warrants monitoring rather than signaling immediate distress.

Taken together, the rating frames RAPP as a name where upside would depend on catalysts outweighing a cash-burning income statement and weak forensic and ownership signals. The valuation tradeoff is that without positive earnings or cash flow, the stock's price cannot be anchored to current earnings multiples, which are not available in source data.

Business

Rapport Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The profile states a market capitalization of $1.2B. Product, customer, and revenue-model details are not available in source data. The FY 2025 and FY 2024 financials report $0.0M of revenue, so the source data does not show a commercial revenue stream in the periods provided.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-125.1M$-111.5MN/A$-88.1M$52.6MN/A
FY 2024$0.0M$-83.1M$-78.3MN/A$-67.2M$56.8MN/A
FY 2023$0.0M$-36.2M$-34.8MN/A$-27.2MN/AN/A

Per the SEC financials, operating losses widened from $-36.2M in FY 2023 to $-125.1M in FY 2025, and free cash flow outflow widened from $-27.2M to $-88.1M over the same span. Gross, operating, and net margins are each reported as 0% in the market data, consistent with no reported revenue. The Roarable RQD rating cites ROIC of -22.9%, an Altman Z-Score of 2.5, and a Piotroski F-Score of 2/9. Cash declined from $56.8M in FY 2024 to $52.6M in FY 2025, while debt is not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news wire, six items are tagged to RAPP:

  • A Yahoo Finance report headlined around a monthly slide of about 29%, tagged YELLOW.
  • A TradingView stock-chart item, tagged YELLOW, with no further specific content in the source.
  • An Investor's Business Daily piece referencing a $4.3 Billion AbbVie market, tagged YELLOW.
  • A Yahoo! Finance Canada quote and history page, tagged YELLOW.
  • An Investing.com report of a CEO stock sale of $143,272, tagged YELLOW. This is an insider transaction item.
  • A Benzinga report of shares falling 20% after hours, tagged RED under the RISK WATCH label.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. The news wire therefore contains the only catalyst and risk information in the source data, and the single RED item is the 20% after-hours decline.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no upstream or downstream links and no proprietary signals. Second-order sector correlations and upstream or downstream bottlenecks are not available in source data. The only cross-company reference in the news wire is the AbbVie market mention, which is a headline reference and does not establish a supply-chain link in the source data.

Open Questions

  • What revenue, if any, does the company generate, and is there any collaboration or licensing income that would explain zero reported revenue?
  • What is the company's cash runway given $52.6M of cash against an FY 2025 free cash outflow of $-88.1M?
  • What is the debt position, which is reported as N/A across the financial periods?
  • What drove the 29% monthly slide and the 20% after-hours decline referenced in the news wire?
  • What are the consensus analyst ratings and price targets, and who are the institutional holders?

RAPP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rapport Therapeutics Inc. (RAPP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RAPP Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RAPP Bull vs. Bear Conversation Board — What's Your Call at $25.05?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RAPP 🐻 67% BEARISH CONVICTION
1. Pick Your Side on RAPP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $21.30 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RAPP (E • RQD 31/100) a Buy at $24.21?

Welcome to the RAPP (Rapport Therapeutics Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $18.88 (-22.0%)
Spot @ $24.21

Pump the brakes on RAPP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RAPP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Rapport Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $30.26 (+25.0%)
Spot @ $24.21

RAPP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RAPP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $24.21 (52-wk range $22.06 - $52.93), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%